What is Raphael Pharm's earnings per share (EPS)?

Raphael Pharm (RAPH) reported diluted earnings per share of $0.07 for fiscal year 2025. This represents a -12.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Raphael Pharm Financials

RAPH

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Raphael Pharm (RAPH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI RAPH FY2025 2026-05-14

Raphael Pharmaceutical is operating on external financing rather than internally generated cash, while liquidity has collapsed and equity turned negative.

The most telling change is that FY2025’s $236K of financing inflow only barely covered the $210K operating cash outflow, leaving cash at just $45K even after burn improved sharply from -$1.42M in FY2021 and -$759K in FY2022. That combination shows a company that has shrunk its cash needs but still cannot self-fund working capital.

The balance-sheet deterioration is steeper than the cash-burn improvement: current liquidity fell from 1.8x in FY2023 to 0.03x in FY2025 as current liabilities jumped from $132K to $1.49M. In operating terms, near-term obligations now outweigh the resources immediately available to meet them.

Meanwhile, capital structure weakened even as financing continued: shares outstanding rose from 18.5M in FY2023 to 20.2M in FY2025, retained losses deepened to -$10.17M, and equity moved from $107K to -$1.43M. That pattern says new capital has mainly been used to keep the entity going, not to rebuild a strong asset base.

Financial Health Signals

Financial Profile 13/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Raphael Pharm's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Raphael Pharm carries a low D/E ratio of -1.04, meaning only $-1.04 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 77/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Raphael Pharm's current ratio of 0.03 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

N/A

EPS (Diluted)

$0.07

YoY-12.5%

Raphael Pharm earned $0.07 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 12.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$45K

YoY+136.8%

5Y CAGR-13.9%

Raphael Pharm held $45K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

20M

YoY+7.9%

5Y CAGR+16.4%

Raphael Pharm had 20M shares outstanding in fiscal year 2025. This represents an increase of 7.9% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

RAPH Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	$569K-51.7%	$1.2M+51.8%	$776K+68.3%	$461K
SG&A Expenses	N/A	N/A	$763K	N/A	$853K+248.2%	$245K
Operating Income	N/A	N/A	N/A	N/A	-$1.6M-130.7%	-$706K
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	N/A	N/A	-$1.6M-126.3%	-$718K
EPS (Diluted)	$0.07-12.5%	$0.080.0%	$0.08-65.2%	$0.23+53.3%	$0.15	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	$141K+95.8%	$72K	N/A	$162K+575.0%	$24K
SG&A Expenses	N/A	N/A	N/A	N/A	$353K	N/A	$157K-30.2%	$225K
Operating Income	N/A	N/A	N/A	N/A	-$425K	N/A	N/A	-$249K
Interest Expense	$3K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	N/A	N/A	-$429K	N/A	N/A	-$248K
EPS (Diluted)	$0.01	N/A	$0.01-50.0%	$0.020.0%	$0.02	N/A	$0.010.0%	$0.01

RAPH Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$53K+96.3%	$27K-88.7%	$239K-28.2%	$333K-21.1%	$422K+30.7%	$323K
Current Assets	$51K+104.0%	$25K-89.5%	$237K-28.4%	$331K-21.6%	$422K+30.7%	$323K
Cash & Equivalents	$45K+136.8%	$19K-91.7%	$230K-20.1%	$288K+88.2%	$153K+61.1%	$95K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.5M+93.2%	$769K+482.6%	$132K-41.9%	$227K-22.8%	$294K-19.7%	$366K
Current Liabilities	$1.5M+93.2%	$769K+482.6%	$132K-41.9%	$227K-22.8%	$294K-19.7%	$366K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$1.4M-93.1%	-$742K-793.5%	$107K+0.9%	$106K-17.2%	$128K+397.7%	-$43K
Retained Earnings	-$10.2M-14.4%	-$8.9M-20.6%	-$7.4M-22.3%	-$6.0M-125.9%	-$2.7M-155.7%	-$1.0M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$3K-94.3%	$53K+657.1%	$7K-76.7%	$30K-67.7%	$93K+244.4%	$27K-47.1%	$51K-60.2%	$128K
Current Assets	$1K-98.0%	$51K+920.0%	$5K-82.1%	$28K-69.2%	$91K+264.0%	$25K-49.0%	$49K-61.1%	$126K
Cash & Equivalents	$1K-97.8%	$45K+1400.0%	$3K-85.0%	$20K-60.0%	$50K+163.2%	$19K-52.5%	$40K-66.7%	$120K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.7M+12.0%	$1.5M+16.9%	$1.3M+17.9%	$1.1M+30.4%	$827K+7.5%	$769K+15.3%	$667K+59.6%	$418K
Current Liabilities	$1.7M+12.0%	$1.5M+16.9%	$1.3M+17.9%	$1.1M+30.4%	$827K+7.5%	$769K+15.3%	$667K+59.6%	$418K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$1.7M-16.0%	-$1.4M-13.4%	-$1.3M-20.6%	-$1.0M-42.8%	-$734K+1.1%	-$742K-20.5%	-$616K-112.4%	-$290K
Retained Earnings	-$10.4M-2.3%	-$10.2M-2.8%	-$9.9M-2.6%	-$9.6M-3.5%	-$9.3M-4.8%	-$8.9M-5.4%	-$8.4M-4.0%	-$8.1M

RAPH Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$210K	N/A	N/A	-$759K+46.5%	-$1.4M-82.2%	-$779K
Capital Expenditures	N/A	N/A	N/A	$2K	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	-$761K	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	-$2K	N/A	N/A
Financing Cash Flow	$236K	N/A	$1.1M+27.8%	$896K-39.3%	$1.5M+79.2%	$824K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	N/A	$46K+370.6%	-$17K+43.3%	-$30K+85.6%	-$209K-237.1%	-$62K+22.5%	-$80K+63.3%	-$218K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	-$4K	$0	$0-100.0%	$240K+485.4%	$41K	$0-100.0%	$50K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

RAPH Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	-1269.5%	N/A
Return on Assets	N/A	N/A	N/A	N/A	-385.1%-162.8pp	-222.3%
Current Ratio	0.030.0	0.03-1.8	1.80+0.3	1.46+0.0	1.44+0.6	0.88
Debt-to-Equity	-1.040.0	-1.04-2.3	1.23-0.9	2.14-0.2	2.30+10.8	-8.51
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	N/A	-461.3%	N/A	N/A	-193.8%
Current Ratio	0.00-0.0	0.03+0.0	0.00-0.0	0.03-0.1	0.11+0.1	0.03-0.0	0.07-0.2	0.30
Debt-to-Equity	-1.00+0.0	-1.04-0.0	-1.01+0.0	-1.03+0.1	-1.13-0.1	-1.04+0.0	-1.08+0.4	-1.44
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$1.4M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.03), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Delivra Health DHBUF

$3.1M

1933 Inds TGIFF

$3.5M

Weed BUDZ

$4.4M

Lftd Partners Inc LIFD

$2.7M

Rafarma Pharmaceuticals Inc. RAFA

$8.6M

Frequently Asked Questions

What is Raphael Pharm's operating cash flow?

Raphael Pharm (RAPH) generated -$210K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Raphael Pharm's total assets?

Raphael Pharm (RAPH) had $53K in total assets as of fiscal year 2025, including both current and long-term assets.

How many shares does Raphael Pharm have outstanding?

Raphael Pharm (RAPH) had 20M shares outstanding as of fiscal year 2025.

What is Raphael Pharm's current ratio?

Raphael Pharm (RAPH) had a current ratio of 0.03 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Raphael Pharm's debt-to-equity ratio?

Raphael Pharm (RAPH) had a debt-to-equity ratio of -1.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Raphael Pharm's cash runway?

Based on fiscal year 2025 data, Raphael Pharm (RAPH) had $45K in cash against an annual operating cash burn of $210K. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Raphael Pharm's debt-to-equity ratio negative or unusual?

Raphael Pharm (RAPH) has negative shareholder equity of -$1.4M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

How financially healthy is Raphael Pharm?

Raphael Pharm (RAPH) scores 13 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.